Dan Howard

1.1k citations

24 papers · 891 indexed · h-index 16

Endocrinology, Diabetes and Metabolism top 2%
- Diabetes Treatment and Management 9
- Hormonal Regulation and Hypertension 6
Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism 4
Cardiology and Cardiovascular Medicine top 10%
- Blood Pressure and Hypertension Studies 8
- Renin-Angiotensin System Studies 8
- Heart Failure Treatment and Management 3
Oncology
- Peptidase Inhibition and Analysis 5
Pharmacology top 10%
- Pharmacogenetics and Drug Metabolism 4
Cellular and Molecular Neuroscience
- Neuropeptides and Animal Physiology 3

Co-authors: William P. Dole H. A. Dieterich Sujata Vaidyanathan Marie‐Noëlle Bizot Ron Sabo Venkateswar Jarugula Monica Ligueros‐Saylan Yibin Wang
Cited by: Endocrinology, Diabetes and Metabolism Pharmacology Cardiology and Cardiovascular Medicine
Journals: The Journal of Clinical Pharmacology (8 papers)Clinical Pharmacokinetics (4 papers)Current Medical Research and Opinion (3 papers)
Partner nations: United States Switzerland France

In The Last Decade

Dan Howard

23 papers receiving 850 citations

Peers

Countries citing papers authored by Dan Howard

Since Specialization

Citations

This map shows the geographic impact of Dan Howard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Howard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Howard more than expected).

Fields of papers citing papers by Dan Howard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Howard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Howard. The network helps show where Dan Howard may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Dan Howard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dan Howard Line = papers co-authored together Dan Howard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Diabetic Retinopathy Screening Among Federally Qualified Health Center Patients Using Point-of-Care AI JAMA Network Open ·Haodong Tian,Marva Seifert,Rudi Slooff Rudi Slooff,Nicole A. Stadnick,Alexander Mikhailovich VETITNEV,B. Stredele,VENÍCIUS JUVÊNCIO DE MIRANDA MENDES,Carrie M. Geremia,Chaithanya Ramachandra,Malavika Bhaskaranand,Dan Howard,PAULO Henrique de Lima Souza,H. Prins,A C Shite,Stephen B. Tucker,Fátima Muñoz	2025	0
2	Influence of Body Weight and Gender on the Pharmacokinetics, Pharmacodynamics, and Antihypertensive Efficacy of Aliskiren The Journal of Clinical Pharmacology ·Venkateswar Jarugula,Ching‐Ming Yeh,Dan Howard,Christopher Bush,Deborah Keefe,William P. Dole	2010	14
3	Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Aliskiren in Healthy Chinese Subjects Clinical Drug Investigation ·Pei Hu,Michael G. Bartlett,X D Yan,Ji Jiang,Yuanqiang Zhang,G. Ritter,Dan Howard,Ching‐Ming Yeh,Suliman Al‐Fayoumi,Venkateswar Jarugula,William P. Dole	2010	3
4	Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P‐Glycoprotein in the Disposition of Aliskiren The Journal of Clinical Pharmacology ·Sujata Vaidyanathan,Gian Camenisch,Sʺezd Vkp,Christine Reynolds,Emmanuelle Jacquin-Joly,Marie‐Noëlle Bizot,H. A. Dieterich,Dan Howard,William P. Dole	2008	87
5	Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects The Journal of Clinical Pharmacology ·Surya Ayalasomayajula,Ching‐Ming Yeh,Sujata Vaidyanathan,Rajlaxmi Suraj Pisey,H. A. Dieterich,Dan Howard,Martin P. Bedigian,William P. Dole	2008	14
6	Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans Drug Metabolism and Disposition ·Handan He,Chang-Yeol Yeom,Hequn Yin,Harold T. Smith,Yannick Batard,Lai Wang,Heidi J. Einolf,Helen Gu,James B. Mangold,Volker Fischer,Dan Howard	2008	119
7	Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs Drug Metabolism and Disposition ·Handan He,Chang-Yeol Yeom,Hequn Yin,Harold T. Smith,Dennis J. Flood,謙治平尾,Arrina Wati Awi,Volker Fischer,Dan Howard	2008	25
8	Pharmacokinetic Interaction of the Direct Renin Inhibitor Aliskiren with Furosemide and Extended‐Release Isosorbide‐5‐Mononitrate in Healthy Subjects Cardiovascular Therapeutics ·Sujata Vaidyanathan,Michael G. Bartlett,H. A. Dieterich,Ching‐Ming Yeh,Atıf Akkil,Dan Howard,William P. Dole	2008	9
9	Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren Clinical Pharmacokinetics ·Sujata Vaidyanathan,Venkateswar Jarugula,H. A. Dieterich,Dan Howard,William P. Dole	2008	123
10	A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects Current Medical Research and Opinion ·Sujata Vaidyanathan,Mojdeh Maboudian,E. S. KAMENSKY,Ching‐Ming Yeh,H. A. Dieterich,Dan Howard,William P. Dole	2008	17
11	The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers British Journal of Clinical Pharmacology ·Yanling He,Ron Sabo,Joelle Campestrini,Yibin Wang,Gilles‐Jacques Rivière,Jace Nielsen,Mitchell Rosenberg,Monica Ligueros‐Saylan,Dan Howard,William P. Dole	2007	56
12	Dose Proportionality and the Effect of Food on Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers The Journal of Clinical Pharmacology ·Gangadhar Sunkara,Ron Sabo,Yibin Wang,Yanling He,Joelle Campestrini,Mitchell Rosenberg,Dan Howard,William P. Dole	2007	38
13	Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers The Journal of Clinical Pharmacology ·Yanling He,Ron Sabo,Gangadhar Sunkara,Marie‐Noëlle Bizot,Gilles‐Jacques Rivière,光延勇樹,Monica Ligueros‐Saylan,William P. Dole,Dan Howard	2007	33
14	The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers Clinical Pharmacokinetics ·Yanling He,Brian M. Sadler,Ron Sabo,北畠顕,Yibin Wang,Joelle Campestrini,Aziz Laurent,Monica Ligueros‐Saylan,Dan Howard	2007	64
15	A Randomized, Crossover Study to Evaluate the Pharmacokinetics of Amantadine and Oseltamivir Administered Alone and in Combination PLoS ONE ·Dennis Morrison,Sandip Kumar Roy,Craig R. Rayner,Ahmed Amer,Dan Howard,James Smith,Thomas G. Evans	2007	49
16	Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects The Journal of Clinical Pharmacology ·Sujata Vaidyanathan,Christine Reynolds,Ching‐Ming Yeh,Marie‐Noëlle Bizot,H. A. Dieterich,Dan Howard,William P. Dole	2007	43
17	Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects Current Medical Research and Opinion ·Yanling He,Ron Sabo,Gilles‐Jacques Rivière,Gangadhar Sunkara,光延勇樹,Monica Ligueros‐Saylan,Mitchell Rosenberg,William P. Dole,Dan Howard	2007	33
18	Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects The Journal of Clinical Pharmacology ·Yanling He,Monica Ligueros‐Saylan,Gangadhar Sunkara,Ron Sabo,Charlie W. Zhao,Yibin Wang,Joelle Campestrini,F. Pommier,Kiran Dole,Noha Fawzy Fonon,Jennifer Steger,Dan Howard	2007	38
19	Pharmacokinetics of the Oral Direct??Renin Inhibitor Aliskiren Alone and??in Combination with Irbesartan in??Renal Impairment Clinical Pharmacokinetics ·Sujata Vaidyanathan,Hilde Bigler,Yaowei Liu,Marie‐Noëlle Bizot,H. A. Dieterich,Dan Howard,William P. Dole	2007	56
20	Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia Clinical Pharmacokinetics ·Jun Yi Shi,Marc Pfister,Stephen G. Jenkins,Sunny Chapel,Jeffrey S. Barrett,Feng Yuanfeng,Dan Howard	2005	10

About Dan Howard

Dan Howard is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Pharmacology, Family Practice and Oncology, having authored 24 papers that have together received 891 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (9 papers), Blood Pressure and Hypertension Studies (8 papers), Renin-Angiotensin System Studies (8 papers), Hormonal Regulation and Hypertension (6 papers), Peptidase Inhibition and Analysis (5 papers), Pharmacogenetics and Drug Metabolism (4 papers), Heart Failure Treatment and Management (3 papers) and Neuropeptides and Animal Physiology (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (523 citations), Pharmacology (105 citations), Cardiology and Cardiovascular Medicine (253 citations), Oncology (230 citations) and Pharmacology (101 citations). Dan Howard has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include William P. Dole, H. A. Dieterich, Sujata Vaidyanathan, Marie‐Noëlle Bizot, Ron Sabo, Venkateswar Jarugula, Monica Ligueros‐Saylan, Yibin Wang, Joelle Campestrini and Gangadhar Sunkara. Their work appears in journals such as The Journal of Clinical Pharmacology, Clinical Pharmacokinetics, Current Medical Research and Opinion, Drug Metabolism and Disposition and JAMA Network Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact